Saskia Litière, Scientific Director at EORTC, shared on LinkedIn:
“It was a pleasure to kick-off ENA 2026 with a Clinical Trial Methodology Workshop on ‘To validate or not to validate: what is the question?’ together with my colleague and co-chair, Madeline Pe.
Our goal was to bring together experts from different endpoint disciplines to explore a fundamental question: When is evidence sufficient to trust an endpoint for decision-making?
The discussions highlighted that while patient-reported outcomes, biomarkers, surrogate endpoints, AI-based measures, and regulatory frameworks have each developed their own validation traditions, they ultimately pursue the same objective: establishing confidence that an endpoint measures the right concept, reliably, meaningfully, and for its intended purpose.
I particularly enjoyed the discussions around what validation actually means, why it matters, and how validation requirements may vary depending on the context and intended use of an endpoint.
As oncology research continues to evolve, these questions are becoming increasingly relevant for both established and novel methodologies.
My sincere thanks to our speakers, Morten Petersen, Tarec Christoffer El-Galaly, Evangelia Christodoulou, and Olli Tenhunen for their insightful contributions, and to all participants for the engaging discussions and thoughtful questions.”
You can also read:
Paolo Bossi: Rethinking Clinical Trial Endpoints for Older Adults With Cancer.
Mark Hensley: The Hidden Risks of Changing Clinical Trial Endpoints After Unblinding.